InnoCan’s LPT-CBD Platform Gains Momentum with Regulatory and Scientific Milestones

InnoCan Pharma has achieved significant progress in its therapeutic development program, announcing both a scientific publication and regulatory alignment that advance its long-acting CBD injection platform. The company confirmed the release of pivotal toxicology study results in the peer-reviewed journal Precision Nanomedicine, demonstrating sustained therapeutic CBD plasma levels from a single subcutaneous injection over a 28-day period. Concurrently, the company has reached agreement with the U.S. Food and Drug Administration on its preclinical development pathway.

Research conducted using Göttingen minipigs, a regulatory-recognized model for predicting human metabolic responses, provided critical validation for InnoCan's liposomal platform technology. The newly published data represent a substantial de-risking event for the pharmaceutical program, addressing both pharmacokinetic performance and safety parameters.

Key research findings include:
- Extended Release Profile: Detectable CBD plasma concentrations persisted throughout the 28-day observation period following a single administration
- Metabolic Correlation: Elevated blood levels of the 7-COOH-CBD metabolite indicate metabolic pathways consistent with human responses
- Favorable Tolerability: No systemic adverse effects were reported, with good local tolerance observed at the injection site

The publication in Precision Nanomedicine provides independent third-party validation of InnoCan's proprietary drug delivery system.

Should investors sell immediately? Or is it worth buying InnoCan Pharma?

Regulatory Pathway Clarified with FDA Agreement

Beyond the scientific achievements, InnoCan's confirmed alignment with FDA officials regarding the preclinical development plan represents a strategic advantage. This regulatory clarity reduces uncertainties often associated with novel drug delivery technologies and establishes a defined framework for progression toward human trials.

The 28-day sustained release capability could transform chronic pain management approaches. Current standards typically involve daily oral medications or frequent injections, creating challenges with patient adherence. InnoCan's platform technology, capable of delivering steady CBD release for extended periods from a single injection, positions LPT-CBD as a potentially disruptive non-opioid alternative.

Next Development Phases

Market attention now shifts to implementation of the FDA-aligned development strategy. The successful minipig data will form the foundation for the Investigational New Drug (IND) application necessary to commence human clinical trials.

Concurrently, InnoCan is enhancing its capital markets strategy. Confirmed participation in the 2025 ThinkEquity Conference signals coordinated efforts to increase visibility among U.S. institutional investors as the company transitions from preclinical research to clinical development.